Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-11-20 Legal Proceedings Report
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Tredje part drar tillbaka överklagande relaterat till Cantargias patent
Legal Proceedings Report Classification · 99% confidence The document is a press release from Cantargia AB announcing that a third party has withdrawn an appeal concerning one of their granted European patents (EP3293202). The text details the legal history of the patent opposition and confirms its validity. The final section explicitly states: 'Denna information är sådan information som Cantargia är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning' (This information is such information that Cantargia is obliged to disclose according to the EU Market Abuse Regulation). This strongly suggests a mandatory regulatory disclosure. Since the content is a specific, non-financial update (legal/patent status) that is not a standard periodic report (10-K, IR, ER) or a management/board change, and it is presented as a formal announcement required by market rules, it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'Legal Proceedings Report' (LTR). Given the focus is on the *withdrawal* of a legal action related to IP, RNS is the most appropriate general regulatory fallback for such specific corporate news that isn't covered by other specific codes like DIRS, DIV, or MANG. The document length (5278 chars) is substantial enough to be the primary document, not just a link announcement (RPA).
2023-11-20 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–September 2023. It contains comprehensive financial statements, including income statements, balance sheet items, and detailed management commentary on business performance, clinical trial progress, and future outlook. It is not an announcement of a report (RPA) but the report itself, as it provides substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. 9M 2023
2023-11-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT' and covers the period 'January – September 2023'. It contains detailed financial statements (net sales, operating loss, loss per share, cash equivalents), management commentary, and operational updates. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2023
2023-11-10 English
Nomination Committee appointed ahead of 2024 Annual General Meeting
AGM Information Classification · 98% confidence The document explicitly discusses the appointment of the Nomination Committee ahead of the '2024 Annual General Meeting (AGM)'. It details the committee members, their tasks related to the AGM (proposing board members, remuneration, etc.), and the date of the AGM. This content is directly related to the preparation and governance surrounding the Annual General Meeting. While it is an announcement, its specific focus on AGM preparatory governance makes 'AGM Information' (AGM-R) a more precise fit than a general 'Report Publication Announcement' (RPA) or 'Governance Information' (CGR), as it is a specific procedural update for the upcoming AGM.
2023-11-03 English
Valberedning utsedd inför årsstämman 2024
Board/Management Information Classification · 99% confidence The document is a formal announcement in Swedish regarding the appointment of the Nomination Committee (Valberedning) ahead of the Annual General Meeting (årsstämman) 2024. It details the committee members, their representation, and their responsibilities concerning board elections and remuneration proposals for the upcoming AGM. This type of announcement, which concerns the preparation for the Annual General Meeting, specifically relates to the governance and procedural aspects leading up to the meeting, which often falls under the scope of AGM-related materials or governance information. Since the core subject is the composition and mandate of the committee responsible for proposing board members and related matters for the AGM, the most fitting category is AGM Information (AGM-R), as it directly relates to the proceedings of the Annual General Meeting. It is not a full report (10-K, IR), a proxy statement (DEF 14A/PSI), or a general regulatory filing (RNS), but a specific announcement about the AGM process.
2023-11-03 Swedish
Cantargia has completed a directed share issue of approximately SEK 59 million
Share Issue/Capital Change Classification · 98% confidence The document is a press release announcing that Cantargia AB has completed a 'directed share issue of approximately SEK 59 million'. This action involves issuing new shares to raise capital, which directly relates to the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves shares, it is a specific financing event rather than a general share repurchase (POS) or a general share issue announcement (SHA), making CAP the most precise fit for a directed issue raising funds. The document is a full announcement, not just a notification that a report is attached, so RPA/RNS is not the primary classification.
2023-10-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.